Halozyme’s primary technology is based on its proprietary recombinant human hyaluronidase enzyme (rHuPH20) that degrades hyaluronan, or HA. HA is a glycosaminoglycan, a chain of natural sugars that is a component of normal tissue, such as skin and cartilage and can also accumulate around many solid cancerous tumors.

Halozyme’s rHuPH20 is a naturally occurring enzyme that temporarily degrades HA, thereby facilitating the dispersion and absorption of other drugs and fluids that are injected under the skin. In oncology, we "pegylate" the enzyme allowing it to circulate longer in the body where it helps degrade HA in the tumor micro environment. By degrading HA, tumor pressure reduces, restoring blood flow and aiding the circulation of co-administered chemotherapies or immunotherapies.

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok